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Abstract 
Fenofibrate, the hypolipidemic drug and peroxisome proliferator, was given to mice (0.23% w/w in the diet) during l-3 weeks and 
enzyme activities, H,O, concentration, and H,O, production rate were determined. A maximal increase of 150% in liver/body weight 
ratio was observed after 3 weeks of treatment. Acyl-CoA oxidase, catalase and uricase activities were increased by 7 I?%, 506% and 41% 
respectively by treatment with fenofibrate. Se- and non Se-glutathione peroxidase and Mn-superoxide dismutase activities were increased 
by 331%, 188% and 130% respectively in the liver of 2 weeks-treated mice. Cu-Zn superoxide dismutase activity was not affected by 
fenofibrate treatment. HzO, steady-state concentration showed an increase of 89% after 2 weeks of treatment. H20, production rates, 
and the steady-state concentrations of the intermediates HO , R and ROO , calculated using experimental data, were higher in the liver of 
fenofibrate-treated mice than in control animals. According to our findings, the imbalance between H202 production and its degradation 
by its metabolizing enzymes during peroxisome proliferation, would result in an increased level of H,O? steady-state concentration, with 
the resulting oxidative stress which may lead to the generation of oxidative damage and to the induction of liver carcinogenesis. 
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1. Introduction 
Xenobiotics, including hypolipidernic drugs, herbicides, 
and phthalate-ester plasticizers, have been found to pro- 
duce hepatomegaly, hepatic peroxisome proliferation. and 
the induction of some peroxisomal oxidizing enzymes, 
particularly the H ,O,-producing acyl-CoA-oxidase, in rats 
and mice [ 1,2]. 
Long-term administration of peroxisome proliferators 
induce a very high incidence of hepatocellular carcinomas 
in rats and mice although they are neither mutagenic in 
Ames assays nor DNA damaging [3]. This led to the 
hypothesis that their carcinogenicity is related to biologi- 
cally active products of the proliferated peroxisomes rather 
than to a direct chemical effect on cellular macromolecules 
141. 
It was proposed that the carcinogenicity of these agents 
may be mediated by oxidative DNA damage resulting 
from persistent peroxisome proliferation and increase in 
* Corresponding author. Fax: +54 I 9627928 
H ,02-generating peroxisomal P-oxidation enzyme system 
in liver [5,6]. 
Goel et al. [7] have shown accumulation of lipofucsin in 
liver during hepatocarcinogenesis by peroxisome prolifera- 
tors. Lipofucsin is widely accepted as the end-product of a 
free radical-induced oxidative polymerization reaction in- 
volving proteins and lipids. Therefore, it seems that xeno- 
biotic-induced peroxisome proliferation may lead to oxida- 
tion of membrane fatty acids. initiating lipid peroxidation 
k91. 
In this study, we developed a model of peroxisome 
proliferation in mice by fenofibrate supplementation of the 
laboratory diet. Fenofibrate belongs to a family of hy- 
polipidemic drugs that are commonly used to prevent 
human cardiovascular risks. 
The aim of this work was to evaluate the H,O, 
metabolism associated to peroxisome proliferation by 
fenofibrate and the levels of antioxidant enzymes. 
2. Materials and methods 
Animals and treatment. Female Swiss mice weighing 
25-30 g were used. Fenofibrate dissolved in ethanol was 
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incorporated into the rodent normal chow, and the solvent 
was evaporated to provide a final fenofibrate concentration 
of 0.23% w/w in the diet. Experimental animals were fed 
the fenofibrate-supplemented diet and control mice were 
fed normal diet subjected to the same procedure but with- 
out the drug for l-3 weeks. 
Preparation of peroxisome-rich fractions. Mice were 
killed by cervical dislocation after 1, 2 or 3 weeks of 
treatment with fenofibrate. The liver was weighed and 
homogeneized in a medium consisting of buffer MSTE 
(0.23 M mannitol, 75 mM sucrose, 10 mM Tris-HCI, 0.2 
mM EDTA) (pH 7.4). Mouse liver homogenates were 
centrifuged at 700 X g for 10 min to discard nuclei and 
cell debris. The supematant (termed ‘homogenate’) was 
centrifuged at 5000 X g for 10 min and the pellet was 
washed after the fluffy layer had been discarded. It was 
considered to consist of mainly heavy intact mitochondria 
and was termed the ‘mitochondrial fraction’. The super- 
natant fractions were centrifuged at 12000 X g for 10 min 
and then were washed, and the collected pellet, including 
the fluffy layer which consists of light mitochondria, per- 
oxisomes, lysosomes and some microsomal membranes, 
was considered to be the ‘peroxisome-rich fraction’. The 
operations were carried out at 0-2°C [IO]. Protein was 
assayed by the method of Lowry et al., using bovine serum 
albumin as standard [ 1 I]. 
Enzyme actiuities. Peroxisomal acyl-CoA-oxidase activ- 
ity was measured by a fluorometric assay based on the 
determination of H,O, production, using the HRP-p-hy- 
droxyphenylacetic acid system [ 121. 
Catalase activity was measured in liver homogenates 
and peroxisomal fractions diluted l/100, treated with 
Triton X-100 and incubated 3 min in a mixture reaction 
containing 20 mM imidazol buffer (pH 7.0), 0.1% BSA, 
and 1.5 mM H,O,. The reaction was stopped by addition 
0.14 
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of titanium IV oxysulphate in 2 N SO,H,. Hydrogen 
peroxide was determined as yellow peroxy titanium sul- 
phate, which absorbs at 405 nm [13]. 
Uricase activity was measured in liver homogenates and 
peroxisomal fractions, by measuring oxygen consumption 
rate during oxidation of uric acid in a medium consisting 
of 50 mM phosphate buffer (pH 7.41, 100 PM uric acid, 5 
kl/ml ethanol and 0.5- 1 .O mg protein. A Clark electrode 
was used for measuring the rate of oxygen consumption. 
Initial oxygen content in the medium reaction is 0.22 mM 
[141. 
Glutathione peroxidase (GPx) was measured in the 
homogenates following NADPH oxidation at 340 nm in 
the presence of reduced glutathione, glutathione reductase 
and tertbutyl hydroperoxide or H,O, as described by 
FlohC and Gunzler [ 151. The activity of glutathione peroxi- 
dase is expressed in U/g liver and the enzyme content is 
also expressed as nmol enzyme/g liver ( PM). 
Cu-Zn superoxide dismutase (Cu-Zn SOD) activity was 
determined in the homogenates by measuring the inhibi- 
tion of the rate of autocatalytic adrenochrome formation in 
a reaction medium containing 1 mM epinephrine and 50 
mM glycine-NaOH (pH 10.2) [ 161. Mn-superoxide dismu- 
tase (Mn-SOD) was assayed in the mitochondrial fractions 
using the same method. Enzyme activity was expressed in 
U/g liver. 
Intracellular steady-state concentration of hydrogen 
peroxide. Tissue slices 0.1 mm thick were incubated 10 
min in 120 mM NaCl, 30 mM phosphate buffer (pH 7.4) at 
30°C and at a tissue/medium ratio of l/20. Samples of 
the incubation medium were diluted l/2.5 with 100 mM 
phosphate buffer (pH 7.4) containing 2.8 U/ml horseradish 
peroxidase and 40 PM p-hydroxyphenylacetic acid as 
hydrogen donor and fluorescence intensity was measured 
at 3 17-414 nm. H?O? concentration was determined by a 
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Fig. I. Effect of the administration of fenofibrate on the wet liver/body weight ratio (0). and on acyl-CoA oxidase (a), catalase (A ) and uricase (0 ) 
activities in liver homogenates. Symbols indicate mean values from 6 animals and bars indicate S.E.M. One unit of acyl-CoA oxidase activity forms I 
nmol H,O,/min under the assay conditions. * P < 0.01; * * P < 0.05. 
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standard calibration curve and calculated by substracting 
the value of a sample treated with 0.1 PM catalase from 
the value of an untreated sample [17]. 
Statistics. Values are expressed as mean values &- S.E.M. 
The significance of differences between mean values were 
analysed by ANOVA and Tukey test. 
3. Results 
Liver/body weight ratio. Wet liver/body weight ratio 
was increased in treated mice at all the studied times. 
Maximal increase of 150% was obtained after 3 weeks of 
treatment (Fig. 1). Water content was not affected by 
fenofibrate treatment (data not shown). 
3. I. Enzyme acticities 
The administration of fenofibrate produced an induction 
of acyl-CoA-oxidase at all the times studied. An increase 
of 712% in the activity of the enzyme was observed in 
homogenates after 2 weeks of treatment (control value: 
287 f 34 U/g liver). One unit of the enzyme forms 1 
nmol H,O,/min under the assay conditions (Fig. 1). 
Specific activity of acyl-CoA oxidase was lo- to 12-fold 
higher in peroxisome-rich fractions after 2 weeks of treat- 
ment (control value: 67 + 5 U/g liver) (Table 1). 
Catalase activity was measured in whole homogenates 
and in peroxisomal fractions of control and treated mice. 
Catalase activity was increased by 506% in liver ho- 
mogenates of fenofibrate-treated mice after 2 weeks of 
treatment (control value: 47 + 7 U/g liver) (Fig. 1). No 
significant changes between control and treated animals 
were observed in the specific catalase activity of peroxi- 
some-rich fractions (Table 1). 
Table 1 
Effect of fenofibrate on the enzyme activity of the peroxisome-rich 
fractions of mouse liver after two weeks of treatment 
Parameter Control Fenofibrate 
Acyl-CoA oxidase (U/g liver) 67+5 848+ 145 * 
Catalase W/g liver) 5.2 i I .o 8.2 + I .2 
Uricase (mu/g liver) 67*9 101~14 
Peroxisomal protein content (mg/g liver) 8.6+0.5 20.6+0.3 ’ 
Values are expressed as mean dc S.E.M. of 4-6 animals. 
* P <O.Ol. 
Uricase activity was measured in whole homogenates 
and in peroxisomal fractions of control and treated mice. 
Uricase activity was increased by 41% in liver ho- 
mogenates of fenofibrate-treated mice after 2 weeks of 
treatment (control value: 1.5 _t 0.1 U/g liver) (Fig. 1). No 
significant changes between control and treated animals 
were observed in uricase activity of peroxisomal fractions 
(Table 1). A slight decrease in uricase activity was ob- 
served in homogenates and in peroxisomal fractions after 8 
days of treatment. 
Se-glutathione peroxidase (Se-GPx) and non-Se-glutath- 
ione peroxidase (non-Se-GPx) were determined in liver 
homogenates of control and treated mice. Administration 
of fenofibrate induced increases in Se and non-Se glu- 
tathione peroxidase activities at all the times of treatment. 
Maximal effects were observed after 2 weeks with in- 
creases of 331% and 188% in Se-GPx and non-Se-GPx 
activities, respectively (control values: Se-GPx: 0.39 L- 0.02 
U/g liver, non-Se-GPx: 0.25 + 0.02 U/g liver) (Fig. 2). 
Cu-Zn superoxide dismutase activity of liver ho- 
mogenates was not affected by fenofibrate treatment as 
compared with control values (631 & 34 U/g liver), while 
Mn-superoxide dismutase activity of the mitochondrial 
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Fig. 2. Se-dependent glutathione peroxidase (Se-GPx) (a), non Se-glutathione peroxidase (non Se-Gpx) (O), Cu-Zn superoxide dismutase (Cu-Zn SOD) 
(A ) and Mn superoxide dismutase (Mn-SOD) (A ) activities in control and fenofibrate-treated mice. Symbols indicate mean values from 6 animals and 
bars indicate S.E.M. * P < 0.01. 
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fractions was increased at all the times studied, with 
maximal increase of 17 1% after 3 weeks of treatment 
(control value: 115 _+ 16 U/g liver) (Fig. 2). 
H202 steady-state concentration. The intracellular 
H,O, steady-state concentration was measured in the incu- 
bation medium of liver slices of control and fenofibrate- 
treated animals after reaching diffusion equilibrium. Ad- 
ministration of fenofibrate during 2 weeks induced an 
increase of 89% in H,O, steady-state concentration (con- 
trol value: 0.09 + 0.01 PM) (Fig. 3). 
H,O, production rates. On the basis of the steady-state 
equations, H,O, production rates were calculated using 
the experimental results of the determinations of H20, 
concentration, catalase and Se-glutathione peroxidase con- 
tent (Eq. 1). 
-d[H,O,]/dt = d[H,O,]/dt 
= k&at][H,O, ] + ko,[GP][H,O, ] 
(Eq. 1) 
Fenofibrate treatment produced a IO-fold increase in the 
calculated H,O, production rate (d[H,O,]/dt calculated), 
two weeks after treatment (Table 2). This increase was 
similar to the one obtained from comparing H,O, produc- 
tion rates corresponding to the measured activity of the 
enzyme acyl CoA-oxidase (d[H *02 ]/dt measured) (Table 
2). 
Lipid peroxidation chain reaction intermediates concen- 
tration. Concentrations of the species hydroxyl radical 
(HO’), alkyl radical (R’) and peroxyl radical (ROO’), 
were calculated by the double steady-state approach and 
the use of published rate constants [ 18-201. Experimental 
data of H,O, concentrations obtained for control and 
15-days-treated animals were used for these calculations. 
HO’ and R’ steady-state concentrations were increased by 
90%, and ROO’ concentration was increased by 37% in 
- 
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Fig. 3. Effect of fenofibrate treatment on liver H?O, steady-state concen- 
tration. Symbols indicate mean values from 6 animals and bars indicate 
S.E.M. * P < 0.01. 
Table 2 
H,O, production rates and lipid peroxidation chain reaction intermedi- 
ates concentrations in the liver of mice after 15 days of treatment with 
fenotibrate 
Time of treatment (days) 
Parameter 0 15 
[H&&I (PM) 0.09 0.17 
[catalase] ( /AM) 1.20 7.26 
[Se-GPx] ( FM) 0.02 0.09 
d[H1O?]/dt ( yM.s-' ) (measured) I.1 14.1 
d[H20>]/dt ( @MY ‘) (calculated) 5.2 58.6 
[HO ’ ] (aM) (calculated) 4.5 8.5 
[R= ] (fM) (calculated) 0.9 1.7 
[ROO ’ ] (nM) (calculated) 0.67 0.92 
the liver of fenofibrate-treated mice, as compared with 
control animals (Table 2). 
4. Discussion 
Peroxisome proliferators are a group of structurally 
diverse compounds that produce similar changes in experi- 
mental animals. These responses occur primarily in hepa- 
tocytes and include enlargement of the liver, increases in 
relative content of peroxisomes and smooth endoplasmic 
reticulum, IO-fold or greater induction of fatty acid p- 
oxidation, camitine acetyltransferase, and lauric acid w- 
hydroxylation activities, and hypolipidemia [2 I]. The hep- 
atomegaly arises from a combination of cellular hypertro- 
phy and hyperplasia [22,23]. Morphometric analysis of 
liver sections from rats treated with peroxisome prolifera- 
tors demonstrated 7- to IO-fold increases in relative peroxi- 
somal volume, which arise from an increase in both the 
volume and number of individual peroxisomes [22,24]. In 
our study, the administration of the hypolipidemic fenofi- 
brate induces hepatomegaly in mice, with an important 
increase in the liver/body weight ratio. Liver water con- 
tent was not affected, indicating that the increase in liver 
weight observed was not due to cellular edema. 
Hypolipidemic agents, such as clofibrate, nafenopin and 
tibric acid are known to produce an induction of the 
peroxisomal @oxidation enzymes and therefore an in- 
creased H,O, production rate [23,251. It has also been 
described that administration of peroxisome proliferators 
such as clofibrate, bezafibrate and di(2-ethylhexyl) phta- 
late, produces an increase of 2- to 3-fold in rat liver 
catalase activity [8]. 
In our study, fenofibrate administration induced a lo- 
to 12-fold increase in acyl CoA-oxidase activity of peroxi- 
somal fractions as compared with control animals, after the 
second week of treatment. A 5-fold increase in catalase 
activity of liver homogenates was observed after 2 weeks 
of treatment with fenofibrate. Specific catalase activity of 
the peroxisomal fractions remained constant; apparently 
the increase in catalase activity observed in the whole 
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homogenates would be a consequence of the increased 
number of peroxisomes. The lack of increase in catalase 
activity of peroxisomal fractions could, at least in part, be 
due to the leakage of catalase during fractionation. Beau- 
fay et al. [26] suggested earlier that during the homoge- 
nization and fractionation of normal rat liver and centrif- 
ugation procedures, there is some catalase release from 
peroxisomes. 
Uricase activity of the homogenates was also increased 
by fenofibrate treatment but to a lesser extent than cata- 
lase. The slight decrease in uricase activity observed dur- 
ing the first week of treatment suggests that there might be 
a proportion of the proliferated peroxisome population 
which are totally or partially deficient in uricase. Hess et 
al. [27] had shown electron micrographs studies of livers 
following treatment with clofibrate in which there was an 
accumulation of microbodies deficient in cores. 
Cu-Zn superoxide dismutase was not affected by fenofi- 
brate treatment, probably because it is not an enzyme 
directly related to H,O, metabolism. However, an in- 
crease in Mn-superoxide dismutase activity was observed 
in fenofibrate-treated mice, suggesting the possibility of 
mitochondrial proliferation, as described by Gear et al. in 
clofibrate-treated rats [28]. Changes within the mitochon- 
drial population have been reported by Meijer et al., with 
increases in the number of mitochondrial profiles and in 
the surface/volume ratio [29]. 
Acyl-CoA oxidase is a FAD-containing enzyme that 
catalyses the first oxidation step of peroxisomal P-oxida- 
tion with reduction of molecular oxygen to hydrogen 
peroxide [30]. The increase in H,O, concentration ob- 
served in our model of peroxisome proliferation, reflects a 
high production of this species at peroxisomal level and 
occurs as a consequence of the induction of the acyl-CoA 
oxidase system. The induction observed in glutathione 
peroxidase could occur as a response to the increased 
steady-state concentration of H *Oz. 
Fenofibrate treatment for 2 weeks produced an increase 
in the Hz02 production rate obtained from calculations, 
and in H,O, production rate corresponding to the mea- 
sured activity of the peroxisomal acyl-CoA oxidase activ- 
ity (Table 2). H?O? production rates obtained from calcu- 
lations (d[H >O?]/dt calculated) were higher than 
dHz02]/dr measured, because they represent total cellu- 
lar H?O? production. 
The high production rate of H,Oz during peroxisome 
proliferation leads to a situation of oxidative stress, which 
is characterized by an increased HzO, steady-state concen- 
tration in hepatic tissue. In the presence of iron traces, 
H,O, can form hydroxyl radical by Fenton type reaction, 
which in turn will attack polyunsaturated fatty acids, initi- 
ating lipid peroxidation process. Steady-state concentration 
of the intermediates HO’, R’ and ROO’ are higher in 
fenofibrate-treated mice than in control mice, suggesting 
that in vivo lipid peroxidation processes might be stimu- 
lated in this model of peroxisome proliferation. 
The oxidative stress hypothesis has been advanced to 
explain how peroxisome proliferation may result in hepato- 
cellular carcinomas. The enhanced H,O, production over- 
comes the ability of peroxisomal catalase and other 
H,O,-degrading enzymes, and results in a slow accumula- 
tion of oxidative damage to the genome [2]. This hypothe- 
sis is supported by evidence of in vivo and in vitro damage 
to DNA associated with proliferated peroxisomes [5,31], 
increased production of hydroxyl radical by proliferated 
peroxisomes [32] and a close association between lipofus- 
tin accumulation and carcinogenesis of peroxisome prolif- 
erators [33,341. 
Treatment with fenofibrate leads to an increase in H?O? 
production rate, that cannot be completely metabolized by 
catalase and diffuses outside the peroxisomes, resulting in 
an increased H,O, steady-state concentration. H,O, can 
produce oxidative damage to DNA and the activation of 
oncogene(s) may lead to the generation of hepatocarcino- 
genesis [7]. 
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